Meeting Overview - The first temporary shareholders' meeting of 2026 was convened by the board of directors on January 9, 2026, at 15:00 [2][3] - The meeting was held both in-person and via online voting, with specific time slots for each voting method [3] Attendance - A total of 527 shareholders and their proxies attended the meeting, representing 1,687,702,885 shares with voting rights, which is 75.6789% of the total voting shares [4] - Among them, 7 shareholders attended in person, representing 1,672,731,019 shares (75.0075%), while 520 participated through online voting, representing 14,971,866 shares (0.6714%) [4][5] - 525 minority shareholders and their proxies attended, representing 77,815,242 shares (3.4893%) [6] Proposal Voting - All proposals were passed with ordinary resolutions, receiving more than half of the valid voting rights from attending shareholders [8] - Proposal 1.00 was voted on with the related shareholders, Sichuan Kelun Pharmaceutical Co., Ltd. and Chengdu Kelun Ninghui Enterprise Management Partnership, abstaining from the vote [8] Legal Opinion - The legal opinion provided by Beijing Zhonglun (Chengdu) Law Firm confirmed that the meeting's convening and voting procedures complied with relevant laws and regulations [10] Documents for Reference - The resolutions from the first temporary shareholders' meeting of 2026 and the legal opinion letter from the law firm are available for review [11]

Group 1 - The company announced the approval of two proposals at the first extraordinary general meeting of shareholders for 2026, including the expected daily related transactions for the year and the allocation of surplus fundraising for other investment projects [1] - The proposals indicate the company's strategic direction for managing its fundraising and investment activities [1] - The approval reflects the company's ongoing commitment to transparency and governance in its financial dealings [1]

四川省成都市高新区天府大道北段 966 号天府国际金融中心南塔 25 层-26 层 邮编：610041 25-26/F, South Tower of Tianfu International Finance Center, 966 North Tianfu Avenue, High-tech Zone, Chengdu, Sichuan 610041, P. R. China 电话/Tel : +86 28 6208 8001 传真/Fax : +86 28 6208 8111 www.zhonglun.com 北京中伦（成都）律师事务所 关于伊犁川宁生物技术股份有限公司 本所律师依据《证券法》《律师事务所从事证券法律业务管理办法》和《律 师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日以前已 经发生或者存在的事实，严格履行了法定职责，遵循勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： ...

1、本次股东会未出现否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 3、本公告中百分比例均保留 4 位小数，若其各分项数值之和与合计数值存 在尾差，均为四舍五入原因造成。 一、会议召开和出席情况 （一）召开情况 1、股东会届次：2026 年第一次临时股东会 证券代码：301301 证券简称：川宁生物 公告编号：2026-001 伊犁川宁生物技术股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： （1）现场会议召开时间：2026 年 1 月 9 日 15:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2026 年 1 月 9 日 9:15-9:25、9:30-11:30 和 13:00-15:00 期间任意时间；通 过深圳证券交易所互联网投票系统投票的具体时间为 2026 年 1 月 9 日 9:15-15:00 期间任意时间。 5、现场会议召开地点：新疆伊犁哈萨克自治州霍尔果斯市经济开发区伊宁 园区拱宸路 1 号 4 楼会议室。 1 6、会议召开方式 ...

Group 1 - The core point of the news is that Chuaning Bio has seen a stock price increase of 5.7%, reaching 10.94 yuan per share, with a trading volume of 1.92 billion yuan and a market capitalization of 24.397 billion yuan as of January 6 [1] - Chuaning Bio, established on December 10, 2010, and listed on December 27, 2022, is located in the Yili Kazakh Autonomous Prefecture of Xinjiang and focuses on the research and industrialization of biological fermentation technology [1] - The company's main business revenue composition is 92.81% from pharmaceutical intermediates and 7.19% from other supplementary sources [1] Group 2 - Among the top ten circulating shareholders of Chuaning Bio, E Fund's Chuangye ETF (159915) reduced its holdings by 2.21% to 13.6694 million shares, resulting in a floating profit of approximately 8.065 million yuan [2] - E Fund's Chuangye ETF was established on September 20, 2011, with a current scale of 110.2 billion yuan, achieving a year-to-date return of 2.86% and a one-year return of 65.9% [2] - The fund manager, Cheng Xi, has a tenure of 9 years and 247 days, with a total asset scale of 250.121 billion yuan, while the other manager, Liu Shurong, has a tenure of 8 years and 175 days, managing assets of 139.916 billion yuan [3]

Group 1 - The core viewpoint of the news is that Chuaning Biological has experienced a decline in both revenue and net profit for the first nine months of 2025, alongside changes in shareholder structure and financing activities [1][2]. Group 2 - As of December 31, Chuaning Biological's stock price remained unchanged at 0.00%, with a trading volume of 46.18 million yuan [1]. - The financing data shows that on December 31, the company had a financing buy-in amount of 4.59 million yuan and a financing repayment of 7.81 million yuan, resulting in a net financing outflow of 3.22 million yuan [1]. - The total balance of margin trading for Chuaning Biological reached 486 million yuan, with a financing balance of 481 million yuan, accounting for 7.65% of the circulating market value, which is below the 20th percentile level over the past year [1]. - In terms of securities lending, on December 31, the company had a securities lending repayment of 30,500 shares and a securities lending sell-out of 27,000 shares, with a sell-out amount of 273,800 yuan [1]. - The company’s securities lending balance was 4.57 million yuan, which is above the 80th percentile level over the past year, indicating a high level of short selling [1]. Group 3 - As of September 30, the number of shareholders for Chuaning Biological was 51,300, a decrease of 5.44% compared to the previous period [2]. - The average circulating shares per person increased by 5.75% to 12,042 shares [2]. - For the period from January to September 2025, Chuaning Biological reported a revenue of 3.436 billion yuan, a year-on-year decrease of 22.90%, and a net profit attributable to shareholders of 611 million yuan, down 43.17% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 1.308 billion yuan in dividends [2]. - Among the top ten circulating shareholders as of September 30, 2025, notable changes include a reduction in holdings by major ETFs, indicating a shift in institutional investment [2].

证券日报网讯 12月24日，川宁生物发布公告称，公司将于2026年1月9日召开2026年第一次临时股东 会。 （文章来源：证券日报） ...

长江证券承销保荐有限公司 关于伊犁川宁生物技术股份有限公司 2026 年度日常关联交易预计的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"或"保荐机构"）作为 伊犁川宁生物技术股份有限公司（以下简称"川宁生物"或"公司"）首次公开 发行股票并在创业板上市持续督导保荐机构，根据《证券发行上市保荐业务管理 办法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上市公 司自律监管指引第 13 号——保荐业务》等有关规定，对公司 2026 年度日常关联 交易预计进行了审慎核查，具体情况如下： 一、日常关联交易基本情况 （一）科伦药业 （一）日常关联交易概述 为满足公司日常生产经营的正常需要，确保公司供销渠道的稳定性，根据公 司2025年度日常关联交易的实际情况，结合公司业务发展需要，预计公司及子公 司与关联方四川科伦药业股份有限公司（以下简称"科伦药业"）及其下属子公 司（以下统称"科伦药业集团"）发生的采购及销售商品、接受及提供劳务；与 关联方伊犁恒辉淀粉有限公司（以下简称"恒辉淀粉"）发生的委托加工原材料 和材料采购； ...

长江证券承销保荐有限公司 长江证券承销保荐有限公司（以下简称"长江保荐"或"保荐机构"）作为 伊犁川宁生物技术股份有限公司（以下简称"川宁生物"或"公司"）首次公开 发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交 易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》及《上市公司募集资金监管规则》等有关法律、法规 及规范性文件的规定，对公司本次部分募投项目结项并将节余募集资金用于其他 募投项目建设事项（以下简称"本次事项"）进行了核查，具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会"证监许可〔2022〕2574 号"文《关于同意伊 犁川宁生物技术股份有限公司首次公开发行股票注册的批复》的批准，公司获准 向社会公众公开发行人民币普通股（A 股）股票 222,800,000 股，每股面值 1.00 元，每股发行价格为人民币 5.00 元，募集资金总额为 1,114,000,000.00 元。扣除 承销保荐费、律师费用、审计费用、信息披露费用、发行手续费用及其他费用共 计 92,316,909.17 元后，公司本次募集资金净 ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-042 伊犁川宁生物技术股份有限公司 关于部分募投项目结项并将节余募集资金用于 其他募投项目建设的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、首次公开发行募集资金的基本情况 经中国证券监督管理委员会"证监许可〔2022〕2574 号"文《关于同意伊 犁川宁生物技术股份有限公司首次公开发行股票注册的批复》的批准，伊犁川宁 生物技术股份有限公司（以下简称"公司"）获准向社会公众公开发行人民币普 通股（A 股）股票 222,800,000 股，每股面值 1.00 元，每股发行价格为人民币 5.00 元，募集资金总额为 1,114,000,000.00 元。扣除承销保荐费、律师费用、审计费 用、信息披露费用、发行手续费用及其他费用共计 92,316,909.17 元后，公司本 次募集资金净额 1,021,683,090.83 元，其中超募资金总额为 421,683,090.83 元。 公司募集资金已于 2022 年 12 月 22 日到账，天健会计师事务所（特殊普通 合伙）已对公司首次公开发 ...